National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 28121-28122 [2021-10965]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 99 / Tuesday, May 25, 2021 / Notices
Information Requested
This RFI requests feedback on two
sections: The need for coordination of
efforts and the scientific focus of a DW
CEC effort. Respondents are free to
address one or both of the sections
listed below and respond to as many
items in each section as they choose,
while remaining within the 10-page
limit, exclusive of attachments.
Section 1—Feedback on Improving
and Coordinating DW CEC Efforts: This
RFI requests feedback on methods to
focus and coordinate DW CEC research
efforts. Please consider how U.S.
Government and external stakeholder
action could contribute to DW CEC
research, take advantage of emerging
science and technology opportunities,
measure outcomes, and develop a DW
CEC research initiative with the goal to
provide safe drinking water for the
American people. Please comment on:
1. Barriers that prevent or limit you or
your organization’s DW CEC research
capabilities and success.
2. Potential opportunities to improve
coordination and partnership among
public and private entities participating
in DW CEC research and prevent
unnecessarily duplicative efforts.
3. The types of outreach efforts most
useful to communicate DW CEC
research results for impacted Federal,
State, local, and Tribal communities.
Please provide examples where
possible.
4. Metrics or indicators that you or
your organization adopted to measure
the success of your DW CEC research or
other related research efforts.
5. Metrics or indicators that would be
valuable in measuring the success of a
National DW CEC research initiative.
6. As an affected community member,
the most significant concerns and
recommendations for DW CECs.
Section 2—Feedback on DW CEC
Research Areas: This RFI requests
feedback on needs for broad areas of DW
CEC research (detailed below) and
research needed for shaping the NECRI.
Research Area 2: Human Health and
Environmental Effects
Emerging contaminants may cause
adverse effects on human health and the
environment. Biological effects research
encompasses the identification and
characterization of these adverse effects,
including factors that influence
susceptibility to disease or disfunction.
Research tools may include in-silico and
receptor-based approaches, predictive
modeling, new toxicological
assessments, and data analytics
strategies. In the context of this research
initiative, environmental effects
research considers indicators of adverse
human health effects.
Research Area 3: Risk Characterization
To Inform Risk Mitigation
Risk characterization synthesizes
available information and
communicates uncertainty about
exposure, biological effects, and other
relevant considerations to inform risk
mitigation actions. Risk mitigation
actions include research into
preventative approaches such as source
reduction. Sustainable chemistry efforts
may also fall into risk mitigation
actions. In addition, treatments,
technological development and
application, and other interventions
may also be considered to reduce or
otherwise mitigate risk for individual,
mixtures, or classes of CEC.
DW CEC Research Areas
Research Area 4: Risk Communication
Below are descriptions of four areas of
DW CEC research identified by the CEC
IWG. When submitting your feedback,
please indicate which DW CEC research
area(s) you are responding to.
Risk communication relays
information to relevant groups about
risks to human health and actions that
could address those risks. The scope of
relevant groups includes those affected
by exposures, the general public,
decision makers, scientists, industry,
and other technical experts. Risk
communication research includes
techniques and media formats used to
inform stakeholder groups and studies
on the psychosocial aspects of risks,
such as general perceptions of risk, the
adoption of risk reduction behaviors,
Research Area 1: Exposure
jbell on DSKJLSW7X2PROD with NOTICES
exposures, characterize their risk, and
develop mitigation tools. Monitoring
can be performed routinely to assess
water composition, during acute
exposure events, or to estimate the effect
of CEC mitigation efforts. Exposure
science includes efforts to estimate the
type and concentration of contaminants
through a range of activities from
targeted analysis of specific CEC, nontargeted analysis for the discovery of
unknown CEC, and modeling activities.
Please include thoughts on
identification and measurement tools,
such as sensors, to conduct analyses.
Exposure to DW CECs can occur
through ingestion, inhalation, or dermal
routes. Exposure-related research
includes contaminant identification and
monitoring from source-to-tap and
informs downstream efforts to
understand the biological effects of CEC
VerDate Sep<11>2014
18:09 May 24, 2021
Jkt 253001
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
28121
and perceptions framed by scientific
controversy or misinformation.
The following statements are
provided to obtain feedback to fill
existing gaps in DW CEC knowledge and
practice in these research areas. Please
comment on:
1. The critical, impactful research
questions and topics that should be
addressed in order to better protect
American public health in regard to DW
CEC.
2. Research priorities within each of
the four areas described below.
3. New or innovative tools,
technologies, software, modeling,
methods, data/information sharing, etc.
that should be developed or employed
to address these research areas.
This RFI is for planning purposes
only and should not be construed as a
solicitation for applications or
proposals, or as an obligation in any
way on the part of the United States
Federal government. The Federal
government will not pay for the
preparation of any information
submitted or for the government’s use.
Additionally, the government cannot
guarantee the confidentiality of the
information provided.
Dated: May 19, 2021.
Christopher P. Weis,
Toxicology Liaison, National Institute of
Environmental Health Sciences, National
Institutes of Health.
[FR Doc. 2021–11051 Filed 5–24–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel Limited Competition:
E:\FR\FM\25MYN1.SGM
25MYN1
28122
Federal Register / Vol. 86, No. 99 / Tuesday, May 25, 2021 / Notices
Facility and Building System Upgrades
Support for the Regional Biocontainment
Laboratories (G20—Clinical Trial Not
Allowed).
Date: June 30, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G42A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Lynn Rust, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G42A, Rockville, MD
20852, (240) 669–5069, lrust@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 19, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–10965 Filed 5–24–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of Centers of Biomedical
Research Excellence (COBRE) Phase 1
Applications.
Date: July 13–14, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892 (Video Meeting).
Contact Person: Nina Sidorova, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institutes of General
VerDate Sep<11>2014
18:09 May 24, 2021
Jkt 253001
Medical Sciences, National Institutes of
Health, 45 Center Drive, Room 3AN18,
Bethesda, MD 20814, 301–402–2783,
sidorova@mail.nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of NIGMS Pathway to
Independence Award K99/R00 Applications.
Date: July 15, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892 (Video Meeting).
Contact Person: Rebecca H. Johnson, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3AN18C, 45 Center
Drive, Bethesda, MD 20892, 301–594–2771,
johnsonrh@nigms.nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of NIGMS Support of
Competitive Research (SCORE) Award
Applications.
Date: July 19, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892 (Video Meeting).
Contact Person: Saraswathy Seetharam,
Ph.D., Scientific Review Officer, Office
Scientific Review, National Institute of
General Medical Sciences, National Institutes
Health, 45 Center Drive, Room 3AN12C,
Bethesda, MD 20892, 301–594–2763,
seetharams@nigms.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: May 20, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11039 Filed 5–24–21; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID: FEMA–2021–0016; OMB No.
1660–0086]
Agency Information Collection
Activities: Proposed Collection;
Comment Request; National Flood
Insurance Program—Mortgage
Portfolio Protection Program (MPPP);
Ask the Advocate Web Form
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: 60-Day notice of revision and
request for comments.
AGENCY:
The Federal Emergency
Management Agency (FEMA), as part of
its continuing effort to reduce
paperwork and respondent burden,
invites the general public to take this
opportunity to comment on a revision of
a previously approved information
collection. In accordance with the
Paperwork Reduction Act of 1995, this
notice seeks comments concerning an
amendment to a currently-approved
collection of information related to the
National Flood Insurance Program
(NFIP), Mortgage Portfolio Protection
Program (MPPP), which is an option
that companies participating in the
NFIP can use to bring their mortgage
loan portfolios into compliance with the
flood insurance purchase requirements.
This notice seeks comments concerning
the collection of information related to
the Office of the Flood Insurance
Advocate (OFIA).
DATES: Comments must be submitted on
or before July 26, 2021.
ADDRESSES: To avoid duplicate
submissions to the docket, please
submit comments at
www.regulations.gov under Docket ID
FEMA–2021–0016. Follow the
instructions for submitting comments.
All submissions received must
include the agency name and Docket ID.
Regardless of the method used for
submitting comments or material, all
submissions will be posted, without
change, to the Federal eRulemaking
Portal at www.regulations.gov, and will
include any personal information you
provide. Therefore, submitting this
information makes it public. You may
wish to read the Privacy and Security
Notice that is available via a link on the
homepage of www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: For
information related to the NFIP
Mortgage Portfolio Protection Program
SUMMARY:
E:\FR\FM\25MYN1.SGM
25MYN1
]]>Agencies
[Federal Register Volume 86, Number 99 (Tuesday, May 25, 2021)]
[Notices]
[Pages 28121-28122]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-10965]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel Limited Competition:
[[Page 28122]]
Facility and Building System Upgrades Support for the Regional
Biocontainment Laboratories (G20--Clinical Trial Not Allowed).
Date: June 30, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G42A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Lynn Rust, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G42A, Rockville, MD
20852, (240) 669-5069, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 19, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-10965 Filed 5-24-21; 8:45 am]
BILLING CODE 4140-01-P
